|
English
|
正體中文
|
简体中文
|
Total items :0
|
|
Visitors :
50697295
Online Users :
339
Project Commissioned by the Ministry of Education
Project Executed by National Taiwan University Library
|
|
|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"gadgeel s"
Showing items 1-6 of 6 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2020-05-26T09:26:36Z |
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer
|
Shaw A.T.;Zeaiter A;Morcos P.N;Balas B;Bordogna W;Golding S;Dansin E;Ahn J.S;Popat S;Lena H;Crino L;Dingemans A.-M.C;Govindan R;Barlesi F;Kim D.-W;Gandhi L;Gadgeel S;De Petris L;Ou S.-H.I;Chih-Hsin Yang; CHIH-HSIN YANG; Ou S.-H.I; De Petris L; Gadgeel S; Gandhi L; Kim D.-W; Barlesi F; Govindan R; Dingemans A.-M.C; Crino L; Lena H; Popat S; Ahn J.S; Dansin E; Golding S; Bordogna W; Balas B; Morcos P.N; Zeaiter A; Shaw A.T. |
| 臺大學術典藏 |
2020-05-26T09:26:36Z |
Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non?�small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria
|
Gadgeel S.;Kotb A;Zeaiter A;Bordogna W;Golding S;Do P;L?na H;Crino L;De Castro J;Chih-Hsin Yang;Hughes B.G.M;Camidge D.R;Kim D.-W;Dingemans A.-M.C;Barlesi F;Shaw A.T;Ignatius Ou S.-H;Gandhi L; Gandhi L; Ignatius Ou S.-H; Shaw A.T; Barlesi F; Dingemans A.-M.C; Kim D.-W; Camidge D.R; Hughes B.G.M; CHIH-HSIN YANG; de Castro J; Crino L; Léna H; Do P; Golding S; Bordogna W; Zeaiter A; Kotb A; Gadgeel S. |
| 臺大學術典藏 |
2020-05-26T09:26:33Z |
Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC
|
Ou S.-H.I.;Kotb A;Gupta R;Liu S;Schulz M;De Marinis F;Kim D.-W;Dingemans A.-M.C;Chih-Hsin Yang;Crin? L;Barlesi F;Shaw A.T;Gadgeel S; Gadgeel S; Shaw A.T; Barlesi F; Crinò L; CHIH-HSIN YANG; Dingemans A.-M.C; Kim D.-W; De Marinis F; Schulz M; Liu S; Gupta R; Kotb A; Ou S.-H.I. |
| 臺大學術典藏 |
2020-05-26T09:26:24Z |
Time to response in patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) receiving alectinib in the phase ii NP28673 and NP28761 studies
|
Gadgeel S;Shaw A.T;Barlesi F;Crino L;Chih-Hsin Yang;Dingemans A.-M;Kim D.-W;Marinis F;Schulz M;Liu S;Gupta R;Smoljanovic V;Ou S.-H.I.; Gadgeel S; Shaw A.T; Barlesi F; Crino L; CHIH-HSIN YANG; Dingemans A.-M; Kim D.-W; Marinis F; Schulz M; Liu S; Gupta R; Smoljanovic V; Ou S.-H.I. |
| 臺大學術典藏 |
2020-05-26T09:26:24Z |
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non?�Small Cell Lung Cancer
|
Borghaei H;Langer C.J;Gadgeel S;Papadimitrakopoulou V.A;Patnaik A;Powell S.F;Gentzler R.D;Martins R.G;Stevenson J.P;Jalal S.I;Panwalkar A;Chih-Hsin Yang;Gubens M;Sequist L.V;Awad M.M;Fiore J;Saraf S;Keller S.M;Gandhi L.; Borghaei H; Langer C.J; Gadgeel S; Papadimitrakopoulou V.A; Patnaik A; Powell S.F; Gentzler R.D; Martins R.G; Stevenson J.P; Jalal S.I; Panwalkar A; CHIH-HSIN YANG; Gubens M; Sequist L.V; Awad M.M; Fiore J; Saraf S; Keller S.M; Gandhi L. |
| 國立臺灣大學 |
2016 |
Time to response in patients with ALK plus NSCLC receiving alectinib in the phase II NP28673 and NP28761 studies
|
Gandhi, L.; Gadgeel, S.; Shaw, A.; Barlesi, F.; Crino, L.; Yang, J. C-H.; Dingemans, A-M. C.; Kim, D-W.; de Marinis, F.; Schulz, M.; Liu, S.; Fish, S.; Kotb, A.; Ou, S-H. I.; 楊志新 |
Showing items 1-6 of 6 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
